Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
55 results about "Abnormal protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In paraproteinemia, abnormal proteins called paraprotein (proteins in the blood or urine), or M component, are produced by a single clone (group) of plasma cells. Such production of abnormal proteins is commonly seen in plasma cell tumors and may also be seen in some other types of tumors.
Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors
ActiveUS20100298358A1Highly effective against hematologicalBiocideNervous disorderAutoimmune conditionPTK Inhibitors
Isolated compounds of formula I:and stereoisomers, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof are described, as well as processes for production, and methods of use of these compounds and compositions thereof for the treatment of diseases associated with abnormal protein kinase activities and / or abnormal histone deacetylase activities including, for example, inflammatory diseases, autoimmune diseases, cancer, neurological and neurodegenerative diseases, cardiovascular diseases, metabolic disease, allergies and asthma and / or hormone-related diseases.
Owner:SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
Kinase inhibitor compounds
Pyridine and pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
Owner:XCOVERY HLDG INC
Spirotricyclic compound, its preparation method, and pharmaceutical composition containing it as well as application thereof
InactiveCN102516263AInhibitory activityInhibition of value addedSenses disorderOrganic chemistryDrugChemical compound
The invention provides a spirotricyclic compound as shown in formula (I), and simultaneously discloses a preparation method of the compound and application thereof, as well as a pharmaceutical composition containing the spirotricyclic compound. Being an inhibitor of protein kinase, the compound in the invention can be used to treat diseases caused by abnormal protein kinase activity, such as tumors and the like.
Owner:SOUTHERN MEDICAL UNIVERSITY
Abnormal protein removing composition
InactiveUS20090041866A1Abnormal protein can be removed or suppressedEase complexityBiocideCosmetic preparationsBletilla striataIris sanguinea
It is an object of the present invention to efficiently remove abnormal protein produced in living tissues, especially skin, due to exposure to UV light, etc.A composition for removing abnormal protein containing one or two or more substances selected from silybin, Bletilla striata extract and Iris sanguinea extract.
Owner:FUAN KERU
Sulfonamide aryl acetylene compound and use thereof
The present invention discloses a sulfonamide aryl acetylene compound having structure characteristics of formula I and a use thereof, and belongs to the technical field of chemical medicines. The compound has an activity of targetedly inhibiting protein kinase, and is able to conduct target treatment of hyperproliferative diseases in human, other mammal tumors, etc. caused by abnormal protein kinase.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Phosphorus containing quinazoline compounds and methods of use
Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.
Owner:JIANGSU KANION PHARMA CO LTD
Phosphorus substituent group-containing quinoline compound and preparation method of quinoline compound as well as pharmaceutical composition containing quinoline compound and application of pharmaceutical composition
The invention provides a phosphorus substituent group-containing quinoline compound as shown in a formula (I). Simultaneously, the invention also discloses a preparation method and an application of the compound as well as a medicament containing the phosphorus substituent group-containing quinoline compound. The compound is an inhibitor of protein kinase, can be used for treating diseases caused by abnormal protein kinase activity, such as tumour and the like.
Owner:BEIJING KONRUNS PHARM CO LTD
Agents for suppressing neural fibrotic degeneration
InactiveUS20090202515A1Suppress neural fibrotic degenerationGreat medical and industrial significanceOrganic active ingredientsNervous disorderSide chainNeural cell
The present invention examined the accumulation of chondroitin sulfate proteoglycans (CSPGs). The present invention relates to neurodegeneration-suppressing agents that are suitable for gene therapy or prevention of neural fibrotic degenerative diseases which induce neural cell death due to an accumulation of abnormal proteins, where the therapies are based on siRNAs against N-acetylgalactosamine-4-O-sulfotransferases (N-acetylgalactosamine-4-O-sulfotransferase-1, N-acetylgalactosamine-4-O-sulfotransferase-2, and N-acetylgalactosamine-4-sulfate 6-O-sulfotransferase (GalNAc4ST-1, GalNAc4ST-2, and GALNAC4S-6ST, respectively)), which are sulfotransferases for acetylgalactosamine, a CSPG side chain, and chondroitinase ABC, an enzyme that degrades chondroitin sulfate, another CSPG side chain.
Owner:STELIC INST OF REGENERATIVE MEDICINE STELIC INST
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
ActiveUS8211901B2Highly effective against hematologicalBiocideNervous disorderPTK InhibitorsEnantiomer
Isolated compounds of formula I:and stereoisomers, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof are described, as well as processes for production, and methods of use of these compounds and compositions thereof for the treatment of diseases associated with abnormal protein kinase activities and / or abnormal histone deacetylase activities including, for example, inflammatory diseases, autoimmune diseases, cancer, neurological and neurodegenerative diseases, cardiovascular diseases, metabolic disease, allergies and asthma and / or hormone-related diseases.
Owner:SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
ActiveUS20160106997A1Improve cognitive functionReduce depositionElectrotherapyMagnetotherapy using coils/electromagnetsCognitionProtein aggregation
A method of treating and preventing a neurological disorder, such as Alzheimer's disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency (preferably ≈300-3,000 MHz) for a predetermined absorption period (preferably greater than ≈3 days). Each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule for a predetermined treatment period. The EMF can have a specific absorption rate up to about 8 W / kg. The methodology enhances cognition in the subject and / or treats / prevents the underlying neurological disorder or a symptom thereof.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
Protein chip used for detecting functional injury of central nervous system and manufacturing method therefor
InactiveCN101008644AHigh speedSpeed up the processMaterial analysisTOR activityBiological activation
This invention relates to one functional central neutral damage dialogue test protein chip and its process method, which comprises the following steps: using protein chip to fix multiple central neutral system damage generation development key function abnormal protein factor antigen and its array; the said protein antigen and its array abnormal protein factors act as key property protein factors in the neutral system for inflammation and activation reaction and cell ion balance adjust and signal transmission.
Owner:陈云 +3
Deuterated trehalose formulations and uses thereof
The presently invention relates to methods, formulations and kits comprising deuterated trehalose for treating myopathies, neurodegenerative disorders, or tauopathies associated abnormal protein aggregation.
Owner:BIOBLAST PHARMA
Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose. Also disclosed is an injectable aqueous pharmaceutical formulation comprising a therapeutically effective amount of trehalose.
Owner:SEELOS THERAPEUTICS INC
Peptides that bind eukaryotic translation initiation factor 4e
InactiveUS20110319338A1Increase serum stabilityEffective cell penetrationPeptide/protein ingredientsVirus peptidesInitiation factorADAMTS Proteins
Methods, compositions and kits for treating proliferative and non-proliferative diseases associated with abnormal protein synthesis. Chimeric peptide constructs are comprised in compositions and kits for use in the treatment of proliferative diseases, such as ovarian cancer, and for inhibiting protein synthesis in a tumor cell compared to a non-tumor cell.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Diagnostic kit for diagnosing disorders or diseases related to abnormal protein aggregation or misfolding of protein using dissolution of protein aggregates
InactiveCN105339798AReduce concentrationLess invasivePeptide/protein ingredientsMicrobiological testing/measurementCell AggregationsMedicine
The present invention relates to a diagnostic kit for diagnosing disorders or diseases related to abnormal protein aggregation or misfolding of protein by using dissolution of protein aggregates in the body, capable of accurately diagnosing disorders or diseases such as Alzheimer's disease caused by aggregation of beta amyloid, as well as disorders and diseases related to abnormal protein aggregation or misfolding of protein by analyzing concentrations through the dissolution of aggregated protein in the blood of a person having other disorders or diseases due to protein aggregation.
Owner:KOREA INST OF SCI & TECH
Phosphorus-containing pyridine[2,3-d]pyrimidine-7-ketone compound or pharmaceutically acceptable salt, pharmaceutical composition and application thereof
InactiveCN105330699AEnhanced inhibitory effectNo apparent toxicityOrganic active ingredientsNervous disorderKinase activityPharmaceutical drug
The invention provides a phosphorus-containing pyridine[2,3-d]pyrimidine-7-ketone compound as shown in the formula (I) or its pharmaceutically acceptable salt, and also discloses a preparation method of the compound, a pharmaceutical composition containing the phosphorus-containing pyridine[2,3-d]pyrimidine-7-ketone compound and an application thereof. The compound is a protein kinase (such as PI3K) inhibitor and can be used in treating diseases caused by abnormal protein kinase activities, such as tumour, etc.
![Phosphorus-containing pyridine[2,3-d]pyrimidine-7-ketone compound or pharmaceutically acceptable salt, pharmaceutical composition and application thereof](https://images-eureka.patsnap.com/patent_img/ae6a22df-dfad-4cfb-9e25-bfb0f8e21a5a/HDA0000553229130000011.PNG "Phosphorus-containing pyridine[2,3-d]pyrimidine-7-ketone compound or pharmaceutically acceptable salt, pharmaceutical composition and application thereof")
![Phosphorus-containing pyridine[2,3-d]pyrimidine-7-ketone compound or pharmaceutically acceptable salt, pharmaceutical composition and application thereof](https://images-eureka.patsnap.com/patent_img/ae6a22df-dfad-4cfb-9e25-bfb0f8e21a5a/HDA0000553229130000012.PNG "Phosphorus-containing pyridine[2,3-d]pyrimidine-7-ketone compound or pharmaceutically acceptable salt, pharmaceutical composition and application thereof")
![Phosphorus-containing pyridine[2,3-d]pyrimidine-7-ketone compound or pharmaceutically acceptable salt, pharmaceutical composition and application thereof](https://images-eureka.patsnap.com/patent_img/ae6a22df-dfad-4cfb-9e25-bfb0f8e21a5a/HDA0000553229130000021.PNG "Phosphorus-containing pyridine[2,3-d]pyrimidine-7-ketone compound or pharmaceutically acceptable salt, pharmaceutical composition and application thereof")
Owner:SHANDONG HUIRUIDI BIOTECH
Abnormal protein removing composition
InactiveUS20090257965A1Good effectPrevent agingCosmetic preparationsBiocideAdditive ingredientProteolysis
Provide an effective composition for removing abnormal protein. Also, a composition for removing abnormal protein whose main ingredient is soyasaponin B group, which is used to provide a composition, agent or food contributing to the prevention or treatment of diseases caused by proteolysis abnormality, among others.
Owner:FUAN KERU
Pretreatment composition, pretreatment method and application of abnormal protein of sugar chain structure suitable for mass spectrometric detection
ActiveCN111381044ASimple requirementsEliminate the effects ofBiological testingAutoimmune conditionAutoimmune disease
The invention relates to a pretreatment composition, a pretreatment method and application of a sugar chain structure abnormal protein suitable for mass spectrometric detection. According to the pretreatment method for the protein with the abnormal sugar chain structure, the protein with the abnormal sugar chain structure in a sample can be accurately separated; the enriched protein with the abnormal sugar chain structure does not need other treatment, and the mass spectrometric detection can be directly carried out; a simple pretreatment method is provided for mass spectrometric detection andanalysis, so a mass spectrometric analyzer can screen and detect related diseases such as tumors and autoimmune diseases. According to the invention, the method has important significance in mass spectrometric detection and extremely high sensitivity; the method is rapid, simple and convenient, and the method can be carried out without magnetic separation equipment or automatic equipment.
Owner:BEIJING SUNGEN BIOMEDICAL TECH CO LTD
Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
Pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
Owner:XCOVERY HLDG INC
Kinase inhibitor compounds
Owner:XCOVERY HLDG
Methods of preparing and using quinazoline and quinoline derivatives
InactiveUS20120225872A1Improve anti-tumor effectUnique structureBiocideOrganic chemistryCancer cellMedicine
A method of preparing a compound of formula (I),A method for treating cancer or inhibiting growth of cancer cells including administering to a patient mammal in need thereof a pharmaceutical preparation including the compound. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal including administering to a mammal a pharmaceutical preparation including the compound.
Owner:TIANJIN HEMAY ONCOLOGY PHARMA CO LTD
Compositions and methods of detecting tiabs
The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by measuring the levels of antibodies against particular aberrant protein domains in a sample from the subject, or the presence or number of immune cells bearing TCR specific for such aberrant protein domains. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects.
Owner:特兰斯麦迪公司
Nisod-like compound and its derivatives for the prevention and treatment of neurodegenerative disorders
ActiveUS20150209370A1Suppress abnormal protein aggregationRelieve pressureOrganic active ingredientsNervous disorderAlzheimer SyndromeBrains tissue
The accumulation of abnormal proteins in neurodegenerative disorders is considered to induce oxidative stress and lead to cell death. Thus suppression of abnormal protein aggregation and reducing oxidative stress or reactive oxygen species (ROS) are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential prevention and treatment of neurodegenerative disorders comprising spinocerebellar ataxia (SCA), Alzheimer's disease (AD) or Parkinson's disease (PD). In the present invention, there are several cell and animal experiment models for SCA, AD and PD established, and NiSOD-like compounds were applied to these experiment models. The results have demonstrated how NiSOD-like compounds are likely to work in suppressing abnormal protein aggregation and reducing oxidative stress; in addition, the results were also confirmed with brain slice culture of SCA17 transgenic mice and AD mice, brain tissues immunostaining of PD mice, and SCA17 transgenic, AD and PD mice.
Owner:NATIONAL TAIWAN NORMAL UNIVERSITY
Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors
InactiveUS7754729B2Improve anti-tumor effectReduced inhibitory activityBiocideOrganic chemistryProtein-Tyrosine KinasesQuinoline
A compound of formula (I),a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of formula (I).
Owner:TIANJIN HEMAY ONCOLOGY PHARMA CO LTD
Protein tyrosine phosphatases or shp2 inhibitors and uses thereof
Small molecule compounds derived from α-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.
Owner:INDIANA UNIV RES & TECH CORP
Abnormal protein removing method
A method for suppressing dull complexion or wrinkles or providing moisture-keeping effect in skin of a subject by removing abnormal protein includes administering to the subject desiring such suppression and moisture-keeping effect a food composition containing a soybean extract containing 40 to 100 parts by weight of soyasaponin B group relative to 100 parts by weight of the soybean extract in an effective amount.
Owner:FUAN KERU
Mutated tau protein fragment and use thereof
ActiveUS20190330293A1Easy to prepareInhibit aggregationCompound screeningNervous disorderAntigenNeutralizing antibody
The present invention relates to a mutated tau protein fragment and a use thereof. The mutated tau protein fragment of the present invention consists of 12 amino acids and thus can easily be prepared. In addition, when the mutated tau protein fragment is injected into an individual as an antigen, a neutralizing antibody against the mutated tau protein is generated. Moreover, the mutated tau protein fragment reduces the aggregation of abnormal tau proteins. Accordingly, the mutated tau protein fragment of the present invention can be effectively used for the prevention or treatment of degenerative neurological diseases.
Owner:ADEL INC
Method for diagnosing diseases through oligomer analysis of abnormally aggregated proteins
ActiveUS20180080946A1Accuracy of diagnosisDisease diagnosisBiological testingBlood plasmaElectrical impedance
The present invention relates to a method for diagnosing a disease using an analysis of oligomer of an abnormal aggregated protein includes: (1) preparing a body fluid sample including at least one of blood, blood plasma, blood serum, saliva, urine, tear, and mucus; (2) making a dilution of the body fluid sample; (3) using a biosensor to measure and detect an aggregated protein in the diluted body fluid sample; (4) analyzing a signal change of the biosensor caused by the dilution of the aggregated protein to determine a slope according to the dilution from the measurements; and (5) analyzing a proportion of the oligomer from the slope according to the dilution to make a diagnosis. The method uses a biosensor to measure the impedance and the protein concentration of blood and detects the slope according to the numerical value of the monomer and the oligomer to diagnose normal or abnormal protein aggregation or the associated diseases with more accuracy.
Owner:KOREA INST OF SCI & TECH
Neurotoxic oligomers
InactiveUS7618634B2Enhance immune responseModest positive reactionSenses disorderNervous disorderCross-linkProtein aggregation
This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.
Owner:THE GENERAL HOSPITAL CORP +1
Neurotoxic oligomers
This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.
Owner:PRANA BIOTECHNOLOGY LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com